Relationship between overexpression of the FLT3 transcript and clinical characteristics in 91 AML cases without FLT3/ITD
. | Total, N = 91 . | FLT3 transcripts more than 200 000 copies/μg RNA, N = 5 . | FLT3 transcripts less than or equal to 200 000 copies/μg RNA, N = 86 . |
---|---|---|---|
Age, y (range) | 48 (15-85) | 43 (21-69) | 48 (15-85) |
Older than 60 y, n | 27 | 2 | 25 |
WBC count, × 109/L (range) | 23.4 (1.2-211) | 56.1 (24.7-197.4) | 22.2 (1.2-211) |
More than 100 × 109/L, n | 14 | 1 | 13 |
FAB | |||
M0 | 2 | 1 | 1 |
M1 | 19 | 1 | 18 |
M2 | 45 | 2 | 43 |
M4 | 18 | 1 | 17 |
M5 | 6 | 0 | 6 |
M6 | 1 | 0 | 1 |
M7 | 0 | 0 | 0 |
Cytogenetics | |||
Favorable | 20 | 1 | 19 |
t(8; 21) | 17 | 1 | 16 |
inv(16) | 3 | 0 | 3 |
Intermediate | 67 | 4 | 63 |
Poor | 4 | 0 | 4 |
t(9; 22) | 2 | 0 | 2 |
del(7) | 2 | 0 | 2 |
Outcome | |||
CR | 71 | 2 | 69 |
Failure | 20 | 3 | 17 |
MLL-TD mutation | 9 | 2 | 7 |
p53 gene mutation | 2 | 0 | 2 |
N-RAS gene mutation | 14 | 1 | 13 |
FLT3/D835 mutation | 5 | 0 | 5 |
. | Total, N = 91 . | FLT3 transcripts more than 200 000 copies/μg RNA, N = 5 . | FLT3 transcripts less than or equal to 200 000 copies/μg RNA, N = 86 . |
---|---|---|---|
Age, y (range) | 48 (15-85) | 43 (21-69) | 48 (15-85) |
Older than 60 y, n | 27 | 2 | 25 |
WBC count, × 109/L (range) | 23.4 (1.2-211) | 56.1 (24.7-197.4) | 22.2 (1.2-211) |
More than 100 × 109/L, n | 14 | 1 | 13 |
FAB | |||
M0 | 2 | 1 | 1 |
M1 | 19 | 1 | 18 |
M2 | 45 | 2 | 43 |
M4 | 18 | 1 | 17 |
M5 | 6 | 0 | 6 |
M6 | 1 | 0 | 1 |
M7 | 0 | 0 | 0 |
Cytogenetics | |||
Favorable | 20 | 1 | 19 |
t(8; 21) | 17 | 1 | 16 |
inv(16) | 3 | 0 | 3 |
Intermediate | 67 | 4 | 63 |
Poor | 4 | 0 | 4 |
t(9; 22) | 2 | 0 | 2 |
del(7) | 2 | 0 | 2 |
Outcome | |||
CR | 71 | 2 | 69 |
Failure | 20 | 3 | 17 |
MLL-TD mutation | 9 | 2 | 7 |
p53 gene mutation | 2 | 0 | 2 |
N-RAS gene mutation | 14 | 1 | 13 |
FLT3/D835 mutation | 5 | 0 | 5 |
Mean (minimum to maximum) values are indicated for age and WBC count. Number of cases is shown by age (> 60 years), WBC count (> 100 × 109/L), FAB, cytogenetics, outcome, and gene mutations. The favorable risk group was defined by t(8;21) or inv(16), the poor risk group by t(9;22) or del(7), and the intermediate risk group by normal or other karyotypes and karyotype unknown. CR indicates complete remission.